Daily Picks for 11/8/16
Welcome to the Daily Picks! Where Uptick staff looks for new companies to feature, giving readers the opportunity to find new possibilities for their investment portfolios.
BRIZF: Brazil Resources Inc.
Brazil Resources Further Increases Size of Private Placement to $9.0 Million and Announces Closing of Initial Tranche of $6.4 Million
Brazil Resources Inc. (the “Company” or “Brazil Resources“) (TSX-V: BRI; OTCQX: BRIZF) is pleased to announce that, further to its press releases dated October 28 and October 31, 2016, it has further increased the size of its previously announced private placement (the “Private Placement“) from aggregate gross proceeds of $6.0 million to $9.0 million, or 3,600,000 units (the “Units“) at a price of $2.50 per Unit, as a result of strong interest received from existing and new investors.
The Company is also pleased to announce that it has completed the initial tranche of the Private Placement and has issued 2,580,732 Units for gross proceeds of $6,451,830 (the “Initial Tranche”).
DFFN: Diffusion Pharmaceuticals Inc.
Diffusion Pharmaceuticals Inc. (OTCQX:DFFN), a clinical stage biotechnology company focused on the development of novel small molecule therapeutics for cancer and other hypoxia-related diseases, today announced that its shares of common stock were approved for listing on the NASDAQ Capital Market. Trading on the NASDAQ Capital Market will commence on November 9, 2016, and the Company’s shares of common stock will continue to trade under the ticker symbol “DFFN.”
David G. Kalergis, Chairman and Chief Executive Officer, stated, “Listing on the NASDAQ Capital Market is an important milestone for Diffusion, and I am extremely pleased to have achieved this goal in the growth of the Company. We expect the NASDAQ listing to enhance the Company’s visibility among investors and allow us to attract a broader and more diverse shareholder base.”
Uptick encourages investors to do their own due diligence in determining investment strategies that work for them. Uptick’s opinion is based upon individual company and market factors. Invest at your own risk.